London celebrations

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey–(Newsfile Corp. – Nov. 10, 2022) – Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on the prevention and treatment of certain inflammatory and oncology, today announced that Cameron Durrant, MD, MBA, President and Chief Executive Officer, will deliver a corporate presentation at 11:25 a.m. EST (4:25 p.m. local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, ifabotuzumab and HGEN005.

A live stream will be available and a webcast link to a recording of the event will be posted in the “Events and Presentations” section of Hunigen’s Investor Relations website for 90 days after the event at www.humanigen.com.

To register for the live webcast, please visit – https://wsw.com/webcast/jeff255/hgen/1834542.

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) is a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions with its product candidates, lenzilumab and ifabotuzumab. Lenzilumab is a Humaneered® monoclonal antibody that binds and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate that GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines. Humanigen is exploring the efficacy of lenzilumab as a treatment for chronic myelomonocytic leukemia and other inflammatory conditions such as acute graft versus host disease in patients undergoing allogeneic hematopoietic stem cell transplantation and as an accompanying therapy for patients receiving CD19-targeted CAR-T cell therapies. Ifabotuzumab (Anti-EphA3) is a Humaneered® monoclonal antibody targeting tumor vasculature. EphA3 has broad expression in human tumors. Initial area of ​​interest may include breast carcinoma, non-small cell lung carcinoma, pancreatic carcinoma, and glioblastoma multiforme. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.

Forward-looking statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgments and expectations regarding future performance or events. Although management believes that the expectations reflected in these statements are reasonable, it does not guarantee that these expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will”, “expect”, “intend”, “plan”, “potential”, “possible”, “goals”, “accelerate”, “continue” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks inherent in our lack of profitability and our need for additional capital to continue our business; that we may not identify strategic alternatives or, where applicable, be able to complete such a transaction on acceptable terms; our reliance on partners to further develop our product candidates; the uncertainties inherent in developing, obtaining required regulatory clearances and approvals, and launching any new pharmaceutical product; the outcome of any pending or future litigation or arbitration; and the various risks and uncertainties described in the “Risk Factors” sections of our most recent annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary statement. You should not rely on forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unforeseen events, or to update the reasons why actual results could differ materially. of those anticipated in the forward-looking statements, in each case, except as required by law.

Investor Relations
Humanity
[email protected]
650-243-3181

Source: Humanigen, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143492